본문 바로가기

Efficacy and safety of fixed-combination brimonidine tartrate/timolol maleate in primary open-angle glaucoma, including normal-tension glaucoma

문서 유형
연구출판물 · 학술지 논문
등재
SCIEScopus
저널 순위
JCR Q3Scopus Q2
저널
JAPANESE JOURNAL OF OPHTHALMOLOGY65(2) · pp.295 · 2021
피인용
Web of Science 2Scopus 4
FWCI (Scopus)
0.33
JCR IF
JCR 2020 2.447
ISSN
0021-5155

저자

  1. Park, Sang Woo제1저자Chonnam National University Hospital, Chonnam National University Medical School, Gwangju, Korea
  2. Kim, Joon MoDepartment of Ophthalmology, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea
  3. 이지웅Pusan National University Hospital, Pusan National University School of Medicine, Busan, Korea
  4. Maglambayan, JoyMedical Affairs, Allergan (an AbbVie company), Singapore, Singapore
  5. Simonyi, SusanMedical Affairs, Allergan (an AbbVie company), Singapore, Singapore
  6. Park, Ki Ho교신저자Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea

초록

Purpose To assess the 12-month efficacy and safety of fixed-combination brimonidine tartrate 0.2%/timolol maleate 0.5% (FCBT) with or without bimatoprost 0.01% (BIM) in primary open-angle glaucoma (POAG), including normal-tension glaucoma (NTG). Study design Prospective, multicenter, open-label study. Methods FCBT was self-administered twice daily after applicable washout (study eye). Intraocular pressure (IOP) was measured at baseline and months 1, 3, 6, 9, and 12. BIM could be added for IOP >= 21 mmHg, IOP reduction from baseline < 20%, or the investigator deemed it necessary. Primary endpoint: mean (11-a.m.) month-12 IOP change from baseline. Secondary endpoints included mean IOP changes from baseline at other visits, median time to achieving and patients (%) achieving target IOP reduction with FCBT, and visual field (VF) progression rate over 12 months. Safety was assessed at each visit. Results Of 118 eyes with POAG (NTG, n = 93), 87 used FCBT; 31 required FCBT + BIM. Mean IOP changes from baseline (16.8 and 15.3 mmHg) to month 12 were - 4.1 mmHg (FCBT, n = 62) and - 3.5 mmHg (FCBT + BIM, n = 15), respectively (both P < 0.0001). Patients who achieved target IOP reduction with FCBT did so in 1 month (median). VF progression rates were 0.17%/year (FCBT, P = 0.8367) and - 0.08%/year (FCBT + BIM, P = 0.9410). Ocular treatment-emergent adverse events occurred in 42.5% (FCBT) and 71.0% (FCBT + BIM) of patients; most were mild and included ocular hyperemia (9.2% and 41.9%, respectively). Conclusions Despite low mean baseline IOP, >= 20% IOP reduction from baseline persisted over 12 months with FCBT and FCBT + BIM, without clinically significant VF progression. Tolerability was consistent with reported drug safety profiles.

키워드

BimatoprostBrimonidine tartrateLow-tension glaucomaTimololHyperemia

식별자

Scopus EID
2-s2.0-85100893825
WoS UID
000618575500001